Calidi Biotherapeutics Presents Data on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform at the 2026 AACR-IO ConferenceGlobeNewsWire • 02/20/26
Calidi Biotherapeutics To Present on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform in a Late-Breaking Abstract at the 2026 AACR-IO ConferenceGlobeNewsWire • 02/12/26
Calidi Biotherapeutics Announces Exclusive Live Investor Webinar and Q&A Session on November 19, 2025GlobeNewsWire • 11/17/25
Calidi Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Operational HighlightsGlobeNewsWire • 11/13/25
Calidi Biotherapeutics Announces Closing of $6.9 Million Underwritten Public Offering and Full Exercise of Underwriters' Over-Allotment OptionGlobeNewsWire • 08/21/25
Calidi Biotherapeutics Announces Pricing of $6 Million Underwritten Public OfferingGlobeNewsWire • 08/20/25
Calidi Biotherapeutics Reports Second Quarter 2025 Financial Results and Recent Operational HighlightsGlobeNewsWire • 08/08/25
Calidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis on August 5, 2025GlobeNewsWire • 07/25/25
Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on July 24GlobeNewsWire • 07/22/25
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Platform Designed to Transform Landscape of Cancer TreatmentGlobeNewsWire • 07/10/25
Calidi Biotherapeutics Announces Exercise of Warrants for $4.6 Million of Gross ProceedsGlobeNewsWire • 07/09/25
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Developing Precision Genetic Medicine Platform for Cancer TreatmentGlobeNewsWire • 07/08/25
Calidi Biotherapeutics, Inc. (CLDI) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?Zacks Investment Research • 05/16/25
Calidi Biotherapeutics Announces Closing of $3.9 Million Registered Direct Offering and Concurrent Private PlacementGlobeNewsWire • 03/31/25
Calidi Biotherapeutics Announces Pricing of $3.9 Million Registered Direct Offering and Concurrent Private PlacementGlobeNewsWire • 03/28/25
Calidi Biotherapeutics Announces Demonstrated Ability To Deliver Transient Gene Therapy (Payload) To Tumors Using Systemic PlatformGlobeNewsWire • 03/10/25
Calidi Biotherapeutics and OS Therapies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVAccesswire • 02/28/25
Calidi Biotherapeutics Announces Commencement of Recruitment for Multiple Dose CLD-101 Trial in Patients with Newly Diagnosed High Grade Glioma at Northwestern University HospitalGlobeNewsWire • 02/24/25
Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on February 5GlobeNewsWire • 01/29/25
Calidi Biotherapeutics Announces Bolstered Cash Balance and Termination of its Standby Equity Purchase AgreementGlobeNewsWire • 01/28/25
Calidi Biotherapeutics Announces Closing of $4.25 Million Public Offering of Common StockGlobeNewsWire • 01/10/25
Calidi Biotherapeutics Announces Pricing of $4.25 Million Public Offering of Common StockGlobeNewsWire • 01/10/25